
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Tilray, Inc is a drug manufacturers-specialty & generic business with stocks listed in the US. Tilray shares (TLRY) are listed on the NASDAQ and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | US$2.43 - US$55.01 |
---|---|
50-day moving average | US$22.4976 |
200-day moving average | US$10.7543 |
Target price | US$18.25 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | US$-1.23 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Revenue TTM | US$191.3 million |
---|---|
Gross profit TTM | US$25.2 million |
Return on assets TTM | -8.76% |
Return on equity TTM | -82.25% |
Profit margin | -141.67% |
Book value | 2.36 |
Market capitalisation | US$4.3 billion |
TTM: trailing 12 months
There are currently 30.8 million Tilray shares held short by investors – that's known as Tilray's "short interest". This figure is 10.5% down from 34.4 million last month.
There are a few different ways that this level of interest in shorting Tilray shares can be evaluated.
Tilray's "short interest ratio" (SIR) is the quantity of Tilray shares currently shorted divided by the average quantity of Tilray shares traded daily (recently around 34.6 million). Tilray's SIR currently stands at 0.89. In other words for every 100,000 Tilray shares traded daily on the market, roughly 890 shares are currently held short.
However Tilray's short interest can also be evaluated against the total number of Tilray shares, or, against the total number of tradable Tilray shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tilray's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Tilray shares in existence, roughly 190 shares are currently held short) or 0.2045% of the tradable shares (for every 100,000 tradable Tilray shares, roughly 205 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tilray.
Find out more about how you can short Tilray stock.
We're not expecting Tilray to pay a dividend over the next 12 months.
Over the last 12 months, Tilray's shares have ranged in value from as little as US$2.43 up to US$55.01. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tilray's is 2.8296. This would suggest that Tilray's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, pharmacies, governments, and hospitals; and for researchers for commercial purposes, as well as compassionate access and clinical research applications. It operates in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, Israel, Ireland, New Zealand, South Africa, Switzerland, the United States, and the United Kingdom. The company was incorporated in 2018 and is headquartered in Nanaimo, Canada.
From Membership Rewards Points to savings on first and business class flights, this charge card is packed with features to help you manage business spending.
From the best sheets for summer to the most luxurious threads, these are the seven best bed sheets you can get in Australia right now.
Everything we know about the Bumble IPO, plus information on how to buy in.
Steps to owning and managing MicroStrategy shares.
Everything we know about the Superhero IPO, plus information on how to buy in.
Everything we know about the Kuaishou IPO, plus information on how to buy in.
Everything we know about the Coinbase IPO, plus information on how to buy in.
Everything we know about the Databricks IPO, plus information on how to buy in.
Steps to owning and managing Ligand Pharmaceuticals shares.
You can't access Robinhood in Australia, so here are five low-cost alternatives to trade US stocks.